Compare ACADIA Pharmaceuticals Inc. (ACAD) vs SMX Security Matters plc (SMX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs SMX Security Matters plc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while SMX Security Matters plc trades at $15.57 (market cap $15.08M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 297.7× SMX Security Matters plc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, SMX Security Matters plc nearer its low. Which is the better fit depends on your goals.
| ACAD | SMX | |
|---|---|---|
Market Cap | $4.49B | $15.08M |
Sector | Health | Technology |
52-Week High | $28.06 | $569.32K |
52-Week Low | $20.06 | $12.87 |
Enterprise Value | $3.69B | $12.05M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
SMX (Security Matters PLC) trades at $16.955, up 12.66% today, following two reverse stock splits in May and June 2026. The technical outlook is neutral with mixed moving averages and oscillators, while fundamentals show a P/B of 1.84 but negative ROE and ROA. Recent news highlights the company's focus on recycled plastic traceability and regulatory tailwinds from state recycling mandates.
Outlook is speculative given negative profitability and recent corporate actions. Investment opportunity hinges on adoption of its Circularity-as-a-Service platform, but risks include execution challenges and intense competition in sustainability tech. Wall Street sentiment appears cautious pending evidence of revenue growth and margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →
